Logo Image
|Articles|July 15, 2021

BioPharm International

  • BioPharm International, 2021 Biopharmaceutical Analysis eBook
  • Volume 2021 eBook
  • Issue 3

Improving IR Spectroscopy as a Tool for Biopharmaceutical Analysis

Microfluidic Modulation Spectroscopy is a recent innovation in infrared spectroscopy techniques that improves elucidation of secondary protein structure.

Over the past two decades, the biopharmaceutical industry, along with the associated regulatory authorities and analytical instrument suppliers, have progressed toward clearer identification of the attributes that are critical for ensuring the quality of biopharmaceuticals and how to measure them efficiently.

The need to understand and predict these molecules’ behavior drives a requirement for new informational insights. This article puts the spotlight on infrared spectroscopy and recent innovations, including the introduction of Microfluidic Modulation Spectroscopy.

Read this article in BioPharm International’s July 2021 Biopharmaceutical Analysis eBook.

About the authors

Holly Lombardo*, HLombardo@redshiftbio.com, is product manager, and Matthew McGann is marketing manager; both are at RedShiftBio.

*To whom all correspondence should be addressed.

Article Details

BioPharm International
eBook: Biopharmaceutical Analysis, July 2021
July 2021
Pages: 31–34

Citation

When referring to this article, please cite it as H. Lombardo and M. McGann, “Improving IR Spectroscopy as a Tool for Biopharmaceutical Analysis," BioPharm International Biopharmaceutical Analysis eBook (July 2021).

Articles in this issue

over 5 years ago

Complex Biomolecules Require Analytical Evolution

over 5 years ago

Best Practices for Analytical Method Validation: Study Design, Analysis, and Acceptance Criteria

over 5 years ago

Data Integrity Considerations for Vendor-Generated Data Associated with Analytical Testing

over 5 years ago

Detecting Residual HCPs Demands a Holistic Approach

over 5 years ago

Increasing the Depth and Reliability of HCP Analysis Using TIMS-MS

over 5 years ago

Prioritizing Cleaning Validation

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more